Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Amicus Therapeutics (FOLD)

Amicus Therapeutics (FOLD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,479,612
  • Shares Outstanding, K 295,383
  • Annual Sales, $ 399,360 K
  • Annual Income, $ -151,580 K
  • 60-Month Beta 0.77
  • Price/Sales 8.77
  • Price/Cash Flow N/A
  • Price/Book 21.13
Trade FOLD with:

Options Overview Details

View History
  • Implied Volatility 45.71% ( -0.15%)
  • Historical Volatility 39.96%
  • IV Percentile 10%
  • IV Rank 32.08%
  • IV High 91.49% on 08/08/23
  • IV Low 24.09% on 06/15/23
  • Put/Call Vol Ratio 0.03
  • Today's Volume 135
  • Volume Avg (30-Day) 610
  • Put/Call OI Ratio 0.57
  • Today's Open Interest 23,929
  • Open Int (30-Day) 22,266

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.06
  • Number of Estimates 6
  • High Estimate -0.03
  • Low Estimate -0.07
  • Prior Year -0.18
  • Growth Rate Est. (year over year) +66.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.32 +4.06%
on 03/26/24
13.60 -13.35%
on 03/01/24
-1.17 (-9.03%)
since 02/28/24
3-Month
11.32 +4.06%
on 03/26/24
14.53 -18.93%
on 01/02/24
-2.74 (-18.87%)
since 12/28/23
52-Week
9.70 +21.44%
on 11/10/23
14.57 -19.15%
on 12/28/23
+0.57 (+5.08%)
since 03/28/23

Most Recent Stories

More News
2 ‘Strong-Buy’-Rated Stocks With Around 50% Upside

Wall Street predicts that these rapidly expanding growth stocks will generate outsized gains this year.

$SPX : 5,254.35 (+0.11%)
$NASX : 16,379.46 (-0.12%)
CVE : 19.99 (+0.76%)
FOLD : 11.78 (-0.67%)
NGG24 : 2.490s (-8.19%)
Amicus Therapeutics: Q3 Earnings Snapshot

Amicus Therapeutics: Q3 Earnings Snapshot

FOLD : 11.78 (-0.67%)
WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease

/PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates...

FOLD : 11.78 (-0.67%)
Nike, Amicus Therapeutics rise; Vail Resorts, Hess fall, Friday, 9/29/2023

Stocks that traded heavily or had substantial price changes on Friday: Nike, Amicus Therapeutics rise; Vail Resorts, Hess fall

OPK : 1.2000 (+12.15%)
MTN : 222.83 (+1.20%)
FOLD : 11.78 (-0.67%)
BLK : 833.70 (-0.17%)
NKE : 93.98 (-0.16%)
WuXi Biologics Reports Solid 2023 Interim Results

Revenue Increased by 17.8% Y-o-Y to RMB8,492.0 Million Adjusted Net Profit Rose by 0.4% to RMB2,925.6 Million Non-COVID Revenue Achieved 59.7% Y-o-Y Growth,...

FOLD : 11.78 (-0.67%)
Amicus Therapeutics: Q2 Earnings Snapshot

Amicus Therapeutics: Q2 Earnings Snapshot

FOLD : 11.78 (-0.67%)
Company News for May 11, 2023

Companies in The news Are: VSH,COHRICL,FOLD

FOLD : 11.78 (-0.67%)
VSH : 22.68 (-0.87%)
COHR : 60.62 (-0.43%)
ICL : 5.38 (+0.37%)
Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Grow

Amicus (FOLD) incurs wider-than-expected loss in the first quarter. Revenues, however, beat estimates. The company reiterates its 2023 guidance.

FOLD : 11.78 (-0.67%)
RCUS : 18.88 (+3.68%)
ALLO : 4.47 (+0.22%)
OCUP : 2.01 (-0.50%)
Amicus Therapeutics (FOLD) Reports Q1 Loss, Tops Revenue Estimates

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -38.46% and 5.03%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

FOLD : 11.78 (-0.67%)
TLIS : 8.75 (-1.41%)
Amicus Therapeutics: Q1 Earnings Snapshot

Amicus Therapeutics: Q1 Earnings Snapshot

FOLD : 11.78 (-0.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Amicus Therapeutics, Inc. is a global patient-centric biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel treatments for patients living with rare metabolic diseases.'The company has one marketed medicine in its portfolio named Galafold which is...

See More

Key Turning Points

3rd Resistance Point 12.42
2nd Resistance Point 12.18
1st Resistance Point 11.98
Last Price 11.78
1st Support Level 11.53
2nd Support Level 11.29
3rd Support Level 11.09

See More

52-Week High 14.57
Fibonacci 61.8% 12.71
Fibonacci 50% 12.14
Last Price 11.78
Fibonacci 38.2% 11.56
52-Week Low 9.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar